CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer

International Journal of Biological Markers

Volumn 11, Issue 2, 1996, Pages 77-81

  Banfi, G ^a   Bravi, S ^a   Ardemagni, A ^a   Zerbi, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CA19.9; CA242; CEA; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; PANCREAS CANCER;

EID: 0029974175     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089601100203     Document Type: Article

References (28)

1. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984; 8: 808-20.
2. Berrino F. Registro Tumori Lombardia. Incidenza dei rumori e cause di morte in Lombardia. Notizie Sanità n. 10, Milano, Regione Lombardia, 1987.
3. Beretta E, Zerbi A, Di Carlo V, et al. Serum CA19.9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 1987; 60: 2428-31.
4. Steinberg WM, Gelfand R, Glenn J, et al. Comparison of the sensitivity and specificity of the CA19.9 and carcinoembryonic antigen assays in detecting cancer of pancreas. Gastroenterology 1986; 60: 343-9.
5. Gupta MK, Arciaja R, Tubbs R. Measurement of a monoclonal antibody-defined antigen (CA19.9) in the sera of patients with malignant and nonmalignant diseases: comparison wth carcinoembryonic antigen. Cancer 1985; 56: 277-81.
6. Baeckström D, Hansson GL, Nilsson O, Johansson C, Gendler SJ, Lindholm L. Purification and characterization of a membrane bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated siayl-Lea epitope on distinct core proteins. J Biol Chem 1991; 266: 21537-47.
7. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini PA. Behaviour of tumor markers CA19.9, CA195, CAM43, CA242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993; 39: 420-3.
8. Pasanen PA, Eskelinen M, Partanen K, Pikkarauren P, Pentilä I, Alhava E. Clinical evaluation of a new serum tumor marker CA242 in pancreatic carcinoma. Br J Cancer 1992; 65: 731-4.
9. Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA242 in gastrointestinal cancer. A comparison with CEA, CA50 and CA19.9. Br J Cancer 1992; 65: 215-21.
10. Hermreck AS. Importance of pathological staging in the surgical management of adenocarcinoma of the exocrine pancreas. Am J Surg 1974; 127: 653-9.
11. Koprowski H, Steplewski Z, Michell K, Herlyn M, Herlyn D, Fuhrer JP. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 457-72.
12. Zucchelli GC, Pilo A, Chiesa MR. Growing use of nonisotopic CA19.9 immunoassay increases between-laboratory variability. Clin Chem 1993; 39: 309-11.
13. Safi F, Beger HG, Bittner R, Büchler M, Kantzberger W. CA19.9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779-83.
14. Klapdor R, Lehmann U, Bahlo M, et al. CA19.9 in der Diagnostik und Differential Diagnostik des exkretorischen Pankreaskarzinoms: Teil 2. Tumor Diagnos Ther 1984; 5: 161.
15. Johansson C, Nilsson O, Baeckström D, Jansson EL, Lindholm L. Novel epitopes on the CA50-carrying antigen: chemical and immunochemical studies. Tumor Biol 1991; 12: 159-70.
16. National Committee for Clinical Laboratory Standards. GP10-P proposed guideline. Villanuova, PA, USA: NCCLS, 1985; 143-69.
17. Angonese C, Basso D, Del Favero G, et al. II CA19.9 sierico nella diagnosi di carcinoma pancreatico: un approccio critico. Ann It Med Int 1987; 2: 138-42.
18. Richter JM, Christensen MR, Rustgi AK et al. The clinical utility of the CA19.9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. A cost effectiveness analysis. Arch Intern Med 1989; 149: 2292-7.
19. Meduri F, Doni MG, Neri D, et al. The role of the leukocyte adherence inhibition (LAI), CA 19.9, and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Cancer 1989; 64: 1103-6.
20. Haglund C. Tumor marker antigen CA125 in pancreatic cancer: a comparison with CA19.9 and CEA. Br J Cancer 1986; 54: 897-901.
21. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumor marker CA242 with CA19.9, CA50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991; 63: 636-40.
22. Rothlin MA, Joller H, Largiader F. CA242 is a new tumor marker for pancreatic cancer. Cancer 1993; 71: 701-7.
23. Pasanen PA, Eskelinen M, Pantanen K, Pikkarainen P, Perttila I, Alhava E. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA50 and CA242 in pancreatic cancer; results from a prospective study. Br J Cancer 1993; 67: 852-8.
24. Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA19.9 for the diagnosis of pancreatic cancer. Br J Cancer 1994; 70: 418.
25. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA242 a new tumor marker for pancreatic cancer. A comparison with CA19.9, CA50 and CEA. Br J Cancer 1994; 70: 487-92.
26. Pålsson B, Masson P, Andren-Sandberg A. The influence of cholestasis on CA50 and CA242 in pancreatic cancer and benign biliopancreatic diseases. Scand J Gastroenterol 1993; 28: 981-7.
27. Del Giudice G, Plebani M, Navaglia F, et al. Il CA242 è realmente un nuovo marcatore tumorale del carcinoma pancreatico? Med Lab 1993; 8: 193 (abstract).
28. Roulston JE. Novel tumor markers: a diagnostic role in pancreatic cancer? Br J Cancer 1994; 70: 389-90.